% | $
Quotes you view appear here for quick access.

Teva Pharmaceutical Industries Limited Message Board

  • maxirnus maxirnus Feb 9, 2013 7:27 PM Flag

    Teva and biosimilars: ·√ⁿ

    "AS BULLISH AS THESE projections are, they don't include the growth potential from a new drug group known as biosimilars, or generic versions of expensive biotech drugs. Hospira is the leading U.S.-based producer of these drugs and among the world's top three, along with Israel's Teva Pharmaceutical (TEVA) and Sandoz, a division of Switzerland's Novartis (NVS). The existing biotech drugs, also known as biologics, are costly in part because they have highly complex molecular structures and are made with live organisms.

    The Bottom Line
    Hospira's stock could rise 30% or more once the company can spend more time and money on its products and less on regula-tory issues. A new generic offering could add even more.
    .An estimated $40 billion of the biologics are scheduled to lose their patent protection through 2020, providing lots of new opportunity for Hospira and its rivals. Datamonitor, a London-based business-research group, has forecast that the biosimilar market will reach nearly $4 billion by 2015 from $243 million in 2010."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • TEVA could easily expand their presence in this market in a meaningful way!

      I hope the talking heads keep the whole patent cliff thing alive for the next few years so we can all accumulate TEVA & other pharma/bio-similar bargains & then wait for 2020 & the huge gains!

      Sentiment: Strong Buy

61.55-0.11(-0.18%)Jul 7 4:01 PMEDT